Using systemic β-AR activation to enrich G-CSF mobilized peripheral blood stem cell grafts with TCR-γδ T-cells could also improve ex vivo graft engineering methods such as TCR-αβ+CD19 depletion (25), which are designed to protect against GvHD and EBV-induced lymphoproliferative disease but retain TCR-γδ T-cells and NK-cells in the graft to maintain anti-tumor activity. Here, CSF3 is linked to neoplasm.